Ascendis Pharma Oncology Division A/S: Financial statements 2020
CVR: 41034076
Source: annual report 2020, Danish Business Authority
13/12/2019 – 31/12/2020
Ascendis Pharma Oncology Division A/S (CVR 41034076) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -35,705,202 and a net result of EUR -36,079,781. Equity in the 2020 report amounted to EUR -28,128,419.
- Gross Profit
- EUR -35,705,202
- Profit/Loss
- EUR -36,079,781
- Equity
- EUR -28,128,419
- Total Assets
- EUR 8,469,083
- Employees
- 0
Official annual report
How creditworthy is Ascendis Pharma Oncology Division A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Ascendis Pharma Oncology Division A/S
Ascendis Pharma Oncology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -85,226,000 and a net result of EUR -110,131,000 compared with EUR -106,375,000 the year before. Equity in the 2025 report amounted to EUR -501,637,000.
